OBJECTIVES: HIV-infected patients on antiretroviral therapy (ART) have an increased cardiovascular disease (CVD) risk as a result of heightened inflammation and immune activation, despite at times having normal lipids and few traditional risk factors. Biomarkers are needed to identify such patients before a clinical event. Lipoprotein-associated phospholipase A2 (Lp-PLA2 ) predicts CVD events in the general population. This study investigated the relationship between Lp-PLA2 and markers of CVD risk, systemic inflammation, immune activation, and coagulation in HIV infection. METHODS: One hundred subjects on stable ART with normal fasting low-density lipoprotein (LDL) cholesterol were enrolled in the study. Plasma Lp-PLA2 concentrations were measured by enzyme-linked immunosorbent assay (ELISA; > 200 ng/mL was considered high CVD risk). Subclinical atherosclerosis, endothelial function, inflammation, immune activation and fasting lipids were also evaluated. RESULTS: The median age of the patients was 47 years and 77% were male. Median (range) Lp-PLA2 was 209 (71-402) ng/mL. Fifty-seven per cent of patients had Lp-PLA2 concentrations > 200 ng/mL. Lp-PLA2 was positively correlated with soluble markers of inflammation or immune activation (tumour necrosis factor receptor-II, intercellular and vascular cellular adhesion molecules, and CD14; all R = 0.3; P < 0.01), and negatively correlated with coagulation markers (D-dimer and fibrinogen; both R = -0.2; P < 0.04). Lp-PLA2 was not correlated with lipids, coronary artery calcium score, or flow-mediated vasodilation, but trended towards a significant correlation with carotid intima-media thickness (R = 0.2; P = 0.05). CONCLUSIONS: In this population with stable ART and normal LDL cholesterol, Lp-PLA2 was in the high CVD risk category in the majority of subjects. Lp-PLA2 appears to be associated with inflammation/immune activation, but also with anti-thrombotic effects. Lp-PLA2 may represent a valuable early biomarker of CVD risk in HIV infection before subclinical atherosclerosis can be detected.
OBJECTIVES:HIV-infectedpatients on antiretroviral therapy (ART) have an increased cardiovascular disease (CVD) risk as a result of heightened inflammation and immune activation, despite at times having normal lipids and few traditional risk factors. Biomarkers are needed to identify such patients before a clinical event. Lipoprotein-associated phospholipase A2 (Lp-PLA2 ) predicts CVD events in the general population. This study investigated the relationship between Lp-PLA2 and markers of CVD risk, systemic inflammation, immune activation, and coagulation in HIV infection. METHODS: One hundred subjects on stable ART with normal fasting low-density lipoprotein (LDL) cholesterol were enrolled in the study. Plasma Lp-PLA2 concentrations were measured by enzyme-linked immunosorbent assay (ELISA; > 200 ng/mL was considered high CVD risk). Subclinical atherosclerosis, endothelial function, inflammation, immune activation and fasting lipids were also evaluated. RESULTS: The median age of the patients was 47 years and 77% were male. Median (range) Lp-PLA2 was 209 (71-402) ng/mL. Fifty-seven per cent of patients had Lp-PLA2 concentrations > 200 ng/mL. Lp-PLA2 was positively correlated with soluble markers of inflammation or immune activation (tumour necrosis factor receptor-II, intercellular and vascular cellular adhesion molecules, and CD14; all R = 0.3; P < 0.01), and negatively correlated with coagulation markers (D-dimer and fibrinogen; both R = -0.2; P < 0.04). Lp-PLA2 was not correlated with lipids, coronary artery calcium score, or flow-mediated vasodilation, but trended towards a significant correlation with carotid intima-media thickness (R = 0.2; P = 0.05). CONCLUSIONS: In this population with stable ART and normal LDL cholesterol, Lp-PLA2 was in the high CVD risk category in the majority of subjects. Lp-PLA2 appears to be associated with inflammation/immune activation, but also with anti-thrombotic effects. Lp-PLA2 may represent a valuable early biomarker of CVD risk in HIV infection before subclinical atherosclerosis can be detected.
Authors: Chris T Longenecker; Corrilynn O Hileman; Teresa L Carman; Allison C Ross; Shabnam Seydafkan; Todd T Brown; Danielle E Labbato; Norma Storer; Vin Tangpricha; Grace A McComsey Journal: Antivir Ther Date: 2011-11-17
Authors: M Chini; A B Tsoupras; N Mangafas; N Tsogas; V D Papakonstantinou; E Fragopoulou; S Antonopoulou; P Gargalianos; C A Demopoulos; M C Lazanas Journal: Int J Immunopathol Pharmacol Date: 2012 Jan-Mar Impact factor: 3.219
Authors: C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe Journal: N Engl J Med Date: 2000-10-19 Impact factor: 91.245
Authors: C T Longenecker; N T Funderburg; Y Jiang; S Debanne; N Storer; D E Labbato; M M Lederman; G A McComsey Journal: HIV Med Date: 2013-01-18 Impact factor: 3.180
Authors: J C Charniot; R Khani-Bittar; J P Albertini; P Giral; C Cherfils; C Cosson; E Guillerm; P Leprince; I Gandjbakhch; D Bonnefont-Rousselot Journal: Int J Cardiol Date: 2012-10-24 Impact factor: 4.164
Authors: Corrilynn O Hileman; Chris T Longenecker; Teresa L Carman; Ginger L Milne; Danielle E Labbato; Norma J Storer; Cynthia A White; Grace A McComsey Journal: Antivir Ther Date: 2012-08-09 Impact factor: 1.679
Authors: Grace Shen; Teressa S Thomas; Allie R Walpert; Colin M McClure; Kathleen V Fitch; Christopher deFilippi; Martin Torriani; Colleen G Buckless; Gail K Adler; Steven K Grinspoon; Suman Srinivasa Journal: Clin Endocrinol (Oxf) Date: 2022-06-06 Impact factor: 3.523
Authors: Mabel Toribio; Min Hi Park; Markella V Zanni; Gregory K Robbins; Tricia H Burdo; Kenneth C Williams; Meghan N Feldpausch; Lauren Stone; Kathleen Melbourne; Steven K Grinspoon; Michael L Fitzgerald Journal: J Clin Endocrinol Metab Date: 2017-11-01 Impact factor: 5.958
Authors: Mabel Toribio; Kathleen V Fitch; Lauren Stone; Markella V Zanni; Janet Lo; Chris de Filippi; Craig A Sponseller; Hang Lee; Ida Grundberg; Melanie A Thompson; Judith A Aberg; Steven K Grinspoon Journal: EBioMedicine Date: 2018-08-31 Impact factor: 8.143
Authors: Udo Hoffmann; Michael T Lu; Borek Foldyna; Markella V Zanni; Julia Karady; Jana Taron; Bingxue K Zhai; Tricia Burdo; Kathleen V Fitch; Emma M Kileel; Kenneth Williams; Carl J Fichtenbaum; Edgar T Overton; Carlos Malvestutto; Judith Aberg; Judith Currier; Craig A Sponseller; Kathleen Melbourne; Michelle Floris-Moore; Cornelius Van Dam; Michael C Keefer; Susan L Koletar; Pamela S Douglas; Heather Ribaudo; Thomas Mayrhofer; Steven K Grinspoon Journal: JAMA Netw Open Date: 2021-06-01
Authors: Alinda G Vos; Nikmah S Idris; Roos E Barth; Kerstin Klipstein-Grobusch; Diederick E Grobbee Journal: PLoS One Date: 2016-01-25 Impact factor: 3.240